Clinical trial
Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
NCT03583164 is registered in ClinicalTrials.gov with F2G Biotech GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
- Lead sponsor
- F2G Biotech GmbH
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 6, 2018
- Completion date
- February 10, 2023
- Enrollment
- 203 (actual)
- Sites
- 82
Conditions
As the registry lists them; a condition with its own page is linked.